Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ...

The US Food and Drug Administration (FDA) has approved the thrombolytic tenecteplase (TNKase, Genentech) for treatment of acute ischemic stroke in adults. The drug is administered as a single ...

Genentech said in a press release that TNKase (tenecteplase) has been approved as a one-time, 5-second IV bolus. It is the second FDA-approved treatment for acute ischemic stroke, the other being ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

Tenecteplase (TNKase) is the first new clot-busting drug to be approved in nearly 30 years, with the U.S. Food and Drug Administration (FDA) giving it the thumbs-up earlier this month. And now ...